Business Context and Reporting Period
Company: Vir Biotechnology, Inc. (VIR)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Vir Bio is a clinical-stage biopharmaceutical company focused on infectious diseases and cancer. Its primary pipeline includes the tobevibart and elebsiran combination for Chronic Hepatitis Delta (CHD) and a portfolio of dual-masked T-cell engagers (TCEs) for solid tumors (VIR-5500, VIR-5818, VIR-5525). The company utilizes proprietary AI (dAIsY) and masking (PRO-XTEN) platforms.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenues | $68.6 million | $74.2 million |
| Net Loss | $(438.0) million | $(522.0) million |
| Operating Loss | $(479.3) million | $(587.2) million |
| Research & Development Expenses | $456.0 million | $506.5 million |
| Cash, Cash Equivalents & Investments | $781.6 million | $1.095 billion |
| Accumulated Deficit | $(1.2) billion | $(760.0) million |
| Net Cash Used in Operating Activities | $(391.8) million | $(446.4) million |
Note: The company has no debt outstanding as of December 31, 2025.
Material Changes vs. Prior Period
- Revenue Composition: Total revenue decreased by 7.6% year-over-year. This was driven by a significant increase in license revenue ($64.3 million) from the Norgine Agreement for CHD commercialization rights in Europe/Australia/New Zealand, partially offset by a decrease in grant revenue (expiration of BARDA and Gates Foundation grants) and lower profit-sharing revenue from GSK following the revocation of sotrovimab's EUA.
- Expense Reduction: Operating expenses decreased by $113.5 million. R&D expenses declined by $50.5 million due to headcount reductions, de-prioritization of programs (influenza, COVID-19), and the absence of a $102.8 million IPR&D expense recognized in 2024 related to the Sanofi acquisition. SG&A expenses decreased by $27.0 million due to restructuring efficiencies.
- Restructuring: The company recorded a net gain of $0.2 million in 2025 compared to $35.0 million in charges in 2024, as major restructuring initiatives were substantially completed in the prior year.
- Liquidity: Cash and investments decreased by approximately $314 million, primarily due to operating cash burn and investment maturities, though the company maintains a runway of at least 12 months.
Guidance, Outlook, and Material Events
Subsequent Event: Astellas Collaboration
On February 19, 2026, Vir Bio entered a global strategic collaboration with Astellas for VIR-5500 (PSMA-targeted TCE for prostate cancer). Key terms include:
- Upfront Consideration: $335 million total ($240 million cash, $75 million equity investment, $20 million near-term milestone).
- Future Milestones: Up to $1.37 billion in development, regulatory, and sales milestones.
- Commercial Rights: Astellas obtains exclusive rights outside the U.S.; Vir Bio retains U.S. rights with profit/loss sharing.
Clinical Pipeline Outlook
- CHD (ECLIPSE Program): Three Phase 3 trials are ongoing. Topline results for ECLIPSE 1 are expected in Q4 2026; ECLIPSE 2 and 3 in Q1 2027. Phase 2 data showed 88% of combination therapy patients achieved undetectable HDV RNA at Week 96.
- Oncology: VIR-5500 Phase 1 dose-escalation is complete; expansion cohorts expected in Q2 2026. VIR-5818 (HER2) and VIR-5525 (EGFR) are advancing in Phase 1.
Risks and Contingencies
- Capital Needs: The company anticipates continued net losses and may require additional financing to fund long-term operations beyond the next 12 months.
- Regulatory: Success depends on regulatory approval of product candidates, which is uncertain. The FDA revoked the EUA for sotrovimab in December 2024, eliminating a potential revenue stream.
- Manufacturing: The company relies on third-party CDMOs for clinical and commercial supply, creating potential supply chain risks.
Investor Verification Checklist
- Astellas Deal Closing: Verify the closing of the Astellas transaction and receipt of the $240 million cash and $75 million equity investment, noting the Hart-Scott-Rodino waiting period.
- ECLIPSE Trial Data: Monitor the Q4 2026 topline data release for ECLIPSE 1, which is critical for the CHD program's regulatory path.
- Cash Burn Rate: Assess the sustainability of the $781.6 million cash balance against the projected operating expenses and the timing of future milestone payments (e.g., to Alnylam and Sanofi).
- Manufacturing Commitments: Review the $44 million in unaccrued manufacturing commitments (Tobevibart/Elebsiran and TCEs) and the ability of CDMOs to meet scale-up requirements.
- Patent Expirations: Confirm the status of key patents for tobevibart (2042) and elebsiran (2039) and the impact of the Sanofi PRO-XTEN license on the oncology portfolio.